Skip to contentHome page Seeking Alpha - Power to InvestorsApr 09, 2026, 12:11 AM ETRigel Pharmaceuticals, Inc. (RIGL) StockStephen Ayers9.67K FollowersCommentsSummaryRigel Pharmaceuticals is upgraded to a speculative Buy as profitability and product momentum improve.Gavreto acquisition has materially boosted revenue and is valued at ~$245M NPV, about half RIGL's market cap.Tavalisse demand surged, carving a defensible niche in ITP; Rezlidhia seeks expansion beyond AML.Pipeline progress (R289, Eli Lilly partnership) and a strong cash position support growth, but new late-stage assets are needed by 2028.Maki Nakamura/DigitalVision via Getty ImagesOverviewMy past hesitation in Rigel Pharmaceuticals (RIGL) was twofold: financial and operational.Financially, Rigel was a microcap stock with a dwindling cash reserve. Operationally, Tavalisse seemed no more than a niche product. And although Rezlidhia had justThis article was written byStephen Ayers9.67K FollowersRN/MBA with a focus on Biotech, Pharma, and Tech sectors. I like to model.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.This article is intended to provide informational content and should not be viewed as an exhaustive analysis of the featured company. It should not be interpreted as personalized investment advice with regard to "Buy/Sell/Hold/Short/Long" recommendations. Financial models presented here, including DCF, rNPV, and scenario analyses, are illustrative tools based on the author's assumptions and are highly sensitive to inputs; small changes can materially alter outputs. The predictions and opinions presented reflect a probabilistic approach, not absolute certainty. Efforts have been made to ensure accuracy, but inadvertent errors may occur. Readers are advised to independently verify information and conduct their own research. Investing in stocks involves inherent volatility and risk. Before making any investment decisions, it is crucial for readers to conduct thorough research and assess their financial circumstances. The author is not liable for any financial losses incurred as a result of using or relying on the content of this article.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.CommentsTo ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.Is this happening to you frequently? Please report it on our feedback forum.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.